Clinical Studies

      Japanese Post-Market Cohort Study

      First posted
      Jan 13, 2017
      Identifier
      NCT03020667
      Publication Site URL
      Topic
      Official Title

      An Observational Cohort Study in Japan to Assess the Patterns of Product Use and Changes in Health Outcomes Associated With the Use of HeatSticks With the IQOS Tobacco Heating System

      Brief Summary

      The objectives and endpoints of this study will be analyzed in the study population of adults legally authorized to buy tobacco products. The study will describe the patterns of use of tobacco and nicotine containing products and self-reported health outcomes and health related events in CC (Cigarette) smokers and IQOS users in Japan.Note: The initial study record (posted to ClinicalTrials.gov) included a clinical sub-study designed to estimate population level differences in the biomarkers of exposure and clinical risk endpoints between IQOS users, CC smokers and never-smokers. However, due to low recruitment and retention of subjects, the clinical sub-study was terminated in May 2017 and the main study was terminated in March 2018. The study protocol was updated to remove the clinical sub-study objectives. This version of the study reflects the latest version of the updated study protocol.

      Summary

      Recruitment: Active, not recruiting

      Study Results: Submitted

      Enrollment: 1124

      Study Type: Observational

      Other IDs: P1-PMC-01-JP

      Related Publications

      Influence of the Introduction of Heated Tobacco Products on IHD and COPD Hospitalizations in Japan using Real-World Data

      Post-Market Studies and Surveillance Study

      Trends in hospitalization due to COPD and IHD before and after the introduction of HTPs in Japan

      Post-Market Studies and Surveillance Study

      Trends in prevalence and patterns of use of a heated tobacco product (IQOS™) in Japan: A three-year repeated cross-sectional study [version 2; peer review: 2 approved with reservations]

      Post-Market Studies and Surveillance Study

      Estimated public health gains from smokers in Germany switching to reduced-risk alternatives: Results from population health impact modelling by socioeconomic group

      Post-Market Studies and Surveillance Study

      Estimated public health gains from German smokers switching to reduced-risk alternatives: Results from population health impact modelling

      Post-Market Studies and Surveillance Study

      Prevalence and patterns of tobacco and/or nicotine product use in Japan (2017) after the launch of a heated tobacco product (IQOS®): a cross-sectional study

      Post-Market Studies and Surveillance Study

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.